ArticlemSphere2022
Detection of Bourbon Virus-Specific Serum Neutralizing Antibodies in Human Serum in Missouri, USA.
Article in mSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Lethal Case of Bourbon Virus Leading to Shock and ECMO Utilization.Case reports in infectious diseases · 2026Article
- Molnupiravir inhibits Bourbon virus infection and disease-associated pathology in mice.Journal of virology · 2025Article
- ANP32 proteins from ticks and vertebrates are key host factors for replication of Bourbon virus across species.Journal of virology · 2025Article
- Surveillance for Serological Evidence of Bourbon and Heartland Virus Infection in White-Tailed Deer and Feral Swine in Texas.Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2025Article
- Serosurveillance Identifies Bourbon Virus-Neutralizing Antibodies in Bobcats, Coyotes, and Red Foxes in Missouri.Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2025Article
- Evidence of Human Bourbon Virus Infections, North Carolina, USA.Emerging infectious diseases · 2024Article
- Serosurveillance and the first detection of Bourbon virus RNA in a wildlife host.bioRxiv : the preprint server for biology · 2024Article
- Tick-Borne Co-Infections: Challenges in Molecular and Serologic Diagnoses.Pathogens (Basel, Switzerland) · 2023Review
- Diversification of Bourbon Virus in New York State.Microorganisms · 2023Article
- Review
- Review of Continuing Medical Education in Tick-Borne Disease for Front-Line Providers.PRiMER (Leawood, Kan.) · 2023Article
- Geographical distribution and pathogenesis of ticks and tick-borne viral diseases.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Bourbon virus (BRBV) was first discovered in 2014 in a fatal human case. Since then it has been detected in the tick Amblyomma americanum in the states of Missouri and Kansas in the United States. Despite the high prevalence of BRBV in ticks in these states, very few human cases have been reported, and the true infection burden of BRBV in the community is unknown. Here, we developed two virus neutralization assays, a vesicular stomatitis virus (VSV)-BRBV pseudotyped rapid assay and a BRBV focus reduction neutralization assay, to assess the seroprevalence of BRBV neutralizing antibodies in human sera collected in 2020 in St. Louis, MO. Of 440 human serum samples tested, three (0.7%) were able to potently neutralize both VSV-BRBV and wild-type BRBV. These findings suggest that human infections with BRBV are more common than previously recognized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.